Oncologists continue to prefer traditional low molecular weight heparins over direct oral anticoagulants (DOAC) for the treatment of venous thromboembolism (VTE) cancer-related. Recently published studies supporting the use DOACs in this patient setting confirm the safety and efficacy of the treatment, but this still does not seem to be enough. The major obstacles to their use are interaction with chemotherapeutic agents, fear of haemorrhage, poor habit of using DOACs for VTE prophylaxis. But what if the haemostasis and thrombosis laboratory reassured oncologists? In this short report we talk about this topic in order to stimulate a fruitful discussion between expert.

Di Gennaro, L., Marazzi, F., De Cristofaro, R., Direct oral anticoagulants in cancer patients: which help from the specialist hemostasis and thrombosis laboratory?, <<MEDICAL ONCOLOGY>>, 2021; 38 (11): 130-131. [doi:10.1007/s12032-021-01585-9] [http://hdl.handle.net/10807/206492]

Direct oral anticoagulants in cancer patients: which help from the specialist hemostasis and thrombosis laboratory?

Di Gennaro, L.
Primo
Conceptualization
;
Marazzi, F.
Penultimo
Data Curation
;
De Cristofaro, R.
Ultimo
Formal Analysis
2021

Abstract

Oncologists continue to prefer traditional low molecular weight heparins over direct oral anticoagulants (DOAC) for the treatment of venous thromboembolism (VTE) cancer-related. Recently published studies supporting the use DOACs in this patient setting confirm the safety and efficacy of the treatment, but this still does not seem to be enough. The major obstacles to their use are interaction with chemotherapeutic agents, fear of haemorrhage, poor habit of using DOACs for VTE prophylaxis. But what if the haemostasis and thrombosis laboratory reassured oncologists? In this short report we talk about this topic in order to stimulate a fruitful discussion between expert.
Inglese
Di Gennaro, L., Marazzi, F., De Cristofaro, R., Direct oral anticoagulants in cancer patients: which help from the specialist hemostasis and thrombosis laboratory?, <<MEDICAL ONCOLOGY>>, 2021; 38 (11): 130-131. [doi:10.1007/s12032-021-01585-9] [http://hdl.handle.net/10807/206492]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/206492
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact